Drugs / GIGA-564
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06258304 | May 2024 → Apr 2026 overdue | — | GigaGen, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-12-12 | Grifols Therapeutics LLC | Regulatory GigaGen Receives FDA clearance of IND to begin Phase 1 Trial of Oncology Drug Candidate, GIGA-564, in solid tumors grifols.com ↗ |
| 2023-11-06 | Grifols Therapeutics LLC | Results GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023 grifols.com ↗
Results also show that GIGA-564 offers increased anti-tumor efficacy and reduced toxicity compared to the commercially available drug ipilimumab, a monoclonal antibody designed to work through CTLA-4 checkpoint inhibition. |
| 2021-07-14 | GigaGen, Inc. | Results GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its anti-CTLA-4 Drug Candidate, GIGA-564 gigagen.com ↗
The publication describes the novel mechanism of action of its anti-CTLA-4 drug candidate, GIGA-564, selected due to its reduced checkpoint inhibition, which resulted in superior anti-tumor activity and lower toxicity in murine models compared to commercially available anti-CTLA-4 drugs. |
All press releases naming this drug 6 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GIGA-564 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06258304 ↗ |
| Action | Inhibit | “a Minimally Blocking Anti-CTLA-4 Monoclonal Antibody” NCT06258304 ↗ |
| Modality | Monoclonal antibody | “a Minimally Blocking Anti-CTLA-4 Monoclonal Antibody” NCT06258304 ↗ |
| Route | Intravenous | “Administered by intravenous infusion” NCT06258304 ↗ |
| Target | CTLA4 | “a Minimally Blocking Anti-CTLA-4 Monoclonal Antibody” NCT06258304 ↗ |